Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H21NO5 |
Molecular Weight | 355.3844 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CCOC(=O)C1=CC(=O)C2=C(O1)C3=CC=C(C)C(C)=C3NC2=O
InChI
InChIKey=NFQIAEMCQGTTIR-UHFFFAOYSA-N
InChI=1S/C20H21NO5/c1-10(2)7-8-25-20(24)15-9-14(22)16-18(26-15)13-6-5-11(3)12(4)17(13)21-19(16)23/h5-6,9-10H,7-8H2,1-4H3,(H,21,23)
Molecular Formula | C20H21NO5 |
Molecular Weight | 355.3844 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://en.pharmacodia.com/web/drug/1_10074.htmlCurator's Comment: Description was created based on several sources, including http://www.kegg.jp/dbget-bin/www_bget?dr:D01890 and https://www.ncbi.nlm.nih.gov/pubmed/1331217
Sources: http://en.pharmacodia.com/web/drug/1_10074.html
Curator's Comment: Description was created based on several sources, including http://www.kegg.jp/dbget-bin/www_bget?dr:D01890 and https://www.ncbi.nlm.nih.gov/pubmed/1331217
Repirinast is an antiallergic drug developed and introduced into the market in Japan in 1987. It is a histamine release inhibitor. It has demonstrated effectiveness for treating bronchial asthma in humans.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Eosinophilia Sources: https://www.ncbi.nlm.nih.gov/pubmed/8386963 |
|||
Target ID: Neutrophilia Sources: https://www.ncbi.nlm.nih.gov/pubmed/8386963 |
|||
Target ID: GO:0097251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2155337 |
100.0 µM [IC50] | ||
Target ID: GO:0001821 Sources: http://adisinsight.springer.com/drugs/800001456 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1331217 |
Primary | Romet Approved UseAsthma |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1331217
For the treatment of atopic asthma - 300 mg twice daily for 7 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2155337
Formations of leukotriene B4 by neutrophils activated with a calcium ionophore (A23187) were effectively inhibited at concentrations 20-200 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:58 GMT 2023
by
admin
on
Fri Dec 15 15:31:58 GMT 2023
|
Record UNII |
4K8KA8B61G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2105300
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
2367
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
100000080809
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
DTXSID10223349
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
C048522
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
CC-84
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
73080-51-0
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
5939
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
4K8KA8B61G
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
C73053
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
m9528
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
5050
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
SUB10281MIG
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY | |||
|
REPIRINAST
Created by
admin on Fri Dec 15 15:31:58 GMT 2023 , Edited by admin on Fri Dec 15 15:31:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |